UroGen's shares drop as the FDA raises concerns about the trial design for UGN-102 bladder cancer treatment.
https://seekingalpha.com/news/4449578-urogen-drops-20-as-fda-releases-docs-in-advance-of-adcom-meeting
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.